Trial Profile
Efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with a diagnosis of recent onset
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Pfizer
- 14 Apr 2008 New trial record.